Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070008/S181

Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr

Biotronik, Inc. · Decision date Oct 9, 2026

MEDTECHLEDGER EXPLANATIONP070008/S181

What did the FDA approve?

The record lists PMA supplement P070008/S181 for Biotronik, Inc. under product code NKE, covering implantable cardiac resynchronization pacemakers. The listed device names are Edora 8 HF-T QP 407137, Edora 8 HF-T 407138, Evity 8 HF-T QP 407139, Evity 8 HF-T 407140, Enitra 8 HF-T QP 407141 and the truncated Enitr entry. The stated change is a battery separator pocket material change plus a new additive to the battery electrolyte; the supplement reason is a change to design, components, specifications or material, filed as a real-time process supplement.

The source does not specify the prior separator pocket material, the identity or quantity of the electrolyte additive, or which listed models each change affects. Nothing in the supplied fields indicates performance testing, battery-life data, or clinical evidence, and the decision does not establish new safety or effectiveness for these pacemakers; it records a component and material change under the original PMA.

FDA approval order statement

battery separator pocket material change and new additive to battery electrolyte.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 9, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P070008/S181
Regulatory pathway
PMA supplement
Product code
NKE
Decision code
APPR
Decision date
Oct 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).

Product code
NKE
FDA device class
3

For the original device and its historical approval scope, see PMA P070008. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P070008 · Original PMA

    STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD

  2. P070008/S181 received

    Application receipt date recorded by FDA.

  3. P070008/S172 · Related supplement

    Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H

  4. P070008/S182 · Related supplement

    Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-

  5. P070008/S181 · FDA decision

    Real-Time Process

  6. P070008/S183 · Related supplement

    Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T

  7. P070008/S184 · Related supplement

    Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR

Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070008

Explore the linked device profile

Other records with product code NKE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records